Carl Zeiss Meditec and Precise Bio have partnered to develop and commercialize fabricated corneal tissue for endothelial keratoplasty and natural lenticule transplants to treat keratoconus and vision correction.
Carl Zeiss Meditec will invest in Precise Bio and fund the development of two cornea transplant products produced with Precise Bio’s 4D biofabrication platform technology while gaining worldwide commercialization rights for the products, according to a press release.
Biofabricated tissue may be used to replace diseased or damaged tissue and substitute for donor tissue by mimicking